Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...
Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...
Goldman Sachs warned there's a risk of a 5% slump in US stocks because ... retreated after President Trump imposed an additional 10% tariff on Chinese goods. Moderna (MRNA) closed down more than -7% ...
China is starting to see a rebound in M&As as government stimulus measures start to bear fruit and pressure from Donald Trump ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
CSL and Cochlear are two of Australia’s blue-chip healthcare stocks, stalwarts of many investors portfolios, whereas Pro ...
New orders also cascaded 16.4 points lower, though were still positive at 17.8. Barclays downgraded Moderna shares to equal ...
Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer ...
Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...
The Dow Jones Industrial Average shed 165.35 points, or 0.37%, closing at 44,546.08. The S&P 500 ticked down 0.01% to ...
Shares of Roku Inc (NASDAQ:ROKU) are up 14.5% in premarket trading, after the streaming giant shared smaller-than-expected losses for the fourth quarter as well as a revenue beat. The company also ...
The company is now expecting 2025 revenue to range from $1.5 billion to $2.5 billion, with a midpoint of $2.0 billion, while FactSet is expecting $2.4 billion. Most of that will come in the second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results